Disclosed is a composition comprising: a semipermeable coating

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long t...

PROBLEM TO BE SOLVED: To provide an ophthalmic emulsion that satisfies both requirements of stability and bioavailability and to provide use of the emulsion for the manufacture of a medicament for treatment particularly of dry eye diseases. SOLUTION: The ophthalmic emulsion comprises colloid particles having an oily core surrounded by an interfacial film. The emulsion contains at least one immunosuppressant (preferably selected from the group consisting of cyclosporine sirolimus and tacrolimus)...

Abstract Ophthalmic oil-in-water emulsions, which comprises colloid 5 particles having an oily core surrounded by an interfacial film, said emulsion comprising an immunosuppressive agent, an oil, preferably at least 50 % of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions, particularly 10 of dry eye diseases. 3078822_1 (GHMatters) P88392.AU I

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long t...

The invention relates to sterile filtered nanoparticulate compositions of beclomethasone and/or budesonide having a surface stabilizer tyloxapol and optionally one or more secondary surface stabilizers absorbed onto the surfaces thereof. The nanoparticulate compositions have an optimal effective average particle size of less than about 150 nm.